Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States-Reference-Cited by-同舟云学术

Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States

Published:2022-04-05 Issue:1 Volume:25 Page:469-480
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Aguiar-Ibáñez Raquel¹^ORCID,Hardern Chloë²,van Hees Frank³,Lee Dawn²^ORCID,Patel Anubhav⁴,Chhabra Nitika⁴,Baluni Gargi⁴,Amonkar Mayur⁵^ORCID,Lai Yizhen⁵,Xu Ruifeng⁵,Massaad Rachid⁶,Fogelman David⁵

Affiliation:

1. Merck Canada Inc., Kirkland, QC, Canada

2. BresMed Health Solutions Ltd., Sheffield, UK

3. BresMed Health Solutions Ltd, Utrecht, Netherlands

4. Complete HEOR Solutions (CHEORS), North Wales, PA, USA

5. Merck & Co., Inc., Kenilworth, NJ, USA

6. MSD (Europe) Inc., Brussels, Belgium

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2022.2043634

Reference38 articles.

1. National Cancer Institute. Cancer stat facts: colorectal cancer; 29 July 2021. Available from: https://seer.cancer.gov/statfacts/html/colorect.html.

2. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

3. Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

4. National Comprehensive Cancer Network. Clinical practice guidelines in oncology (NCCN Guidelines) – rectal cancer; version 1.2021; 2021 [accessed 2021 July 6]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf.

5. National Comprehensive Cancer Network. Clinical practice guidelines in oncology (NCCN Guidelines) – colon cancer; version 2.2021; 2021 [accessed 2021 Jul 6]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Performance of Low-Dose Immunotherapy and Standard-Dose Immunotherapy in Microsatellite Instability-High Metastatic Colorectal Cancer: Real-World Data (CLouD—High Study);JCO Global Oncology;2024-08

2. Multifactorial risk prediction analysis of liver metastasis in colorectal cancer: incorporating programmed cell death ligand 1 combined positive score and other factors;Journal of Gastrointestinal Surgery;2024-08

3. Evaluating the KEYNOTE-057 trial's findings: addressing demographic, methodological, and economic considerations;The Lancet Oncology;2024-08

4. Immunotherapy in Colorectal Cancer — Finding the Achilles’ Heel;NEJM Evidence;2024-05-28

5. Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK;Journal of Medical Economics;2024-02-19